AbstractsGenitourinary tumours, non-prostate845O - Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)
Genitourinary tumours, non-prostate
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2017 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.